Cargando…
Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation?
We report on the successful treatment of a severe, recalcitrant dermatitis caused by CTLA-4 insufficiency with dupilumab, raising the possibility of a role of type 2 immunity in clinical conditions associated with CTLA-4 insufficiency.
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509893/ https://www.ncbi.nlm.nih.gov/pubmed/37780100 http://dx.doi.org/10.1016/j.jacig.2022.08.004 |
| _version_ | 1785107851974279168 |
|---|---|
| author | Arruda, L. Karla Cordeiro, Daniel L. Langer, Sarah S. Koenigham-Santos, Marcel Calado, Rodrigo T. Dias, Marina M. Anhesini, Leonardo R. Oliveira, João Bosco Grimbacher, Bodo Ferriani, Mariana P.L. |
| author_facet | Arruda, L. Karla Cordeiro, Daniel L. Langer, Sarah S. Koenigham-Santos, Marcel Calado, Rodrigo T. Dias, Marina M. Anhesini, Leonardo R. Oliveira, João Bosco Grimbacher, Bodo Ferriani, Mariana P.L. |
| author_sort | Arruda, L. Karla |
| collection | PubMed |
| description | We report on the successful treatment of a severe, recalcitrant dermatitis caused by CTLA-4 insufficiency with dupilumab, raising the possibility of a role of type 2 immunity in clinical conditions associated with CTLA-4 insufficiency. |
| format | Online Article Text |
| id | pubmed-10509893 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105098932023-09-29 Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation? Arruda, L. Karla Cordeiro, Daniel L. Langer, Sarah S. Koenigham-Santos, Marcel Calado, Rodrigo T. Dias, Marina M. Anhesini, Leonardo R. Oliveira, João Bosco Grimbacher, Bodo Ferriani, Mariana P.L. J Allergy Clin Immunol Glob Case Report We report on the successful treatment of a severe, recalcitrant dermatitis caused by CTLA-4 insufficiency with dupilumab, raising the possibility of a role of type 2 immunity in clinical conditions associated with CTLA-4 insufficiency. Elsevier 2022-09-22 /pmc/articles/PMC10509893/ /pubmed/37780100 http://dx.doi.org/10.1016/j.jacig.2022.08.004 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Case Report Arruda, L. Karla Cordeiro, Daniel L. Langer, Sarah S. Koenigham-Santos, Marcel Calado, Rodrigo T. Dias, Marina M. Anhesini, Leonardo R. Oliveira, João Bosco Grimbacher, Bodo Ferriani, Mariana P.L. Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation? |
| title | Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation? |
| title_full | Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation? |
| title_fullStr | Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation? |
| title_full_unstemmed | Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation? |
| title_short | Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation? |
| title_sort | efficacy of dupilumab for the treatment of severe skin disease in cytotoxic t lymphocyte antigen-4 insufficiency: a role of type 2 inflammation? |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509893/ https://www.ncbi.nlm.nih.gov/pubmed/37780100 http://dx.doi.org/10.1016/j.jacig.2022.08.004 |
| work_keys_str_mv | AT arrudalkarla efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT cordeirodaniell efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT langersarahs efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT koenighamsantosmarcel efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT caladorodrigot efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT diasmarinam efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT anhesinileonardor efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT oliveirajoaobosco efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT grimbacherbodo efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation AT ferrianimarianapl efficacyofdupilumabforthetreatmentofsevereskindiseaseincytotoxictlymphocyteantigen4insufficiencyaroleoftype2inflammation |